Previous 10 | Next 10 |
Statera Biopharma (NASDAQ:STAB) soars 10.2% premarket after submitting its Phase 3 clinical trial protocol for STAT-201 in the treatment of pediatric Crohn’s Disease (CD) to the FDA. The Phase 3 trial will evaluate the safety and efficacy of STAT-201 compared to placebo ...
FORT COLLINS, Colo., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced submission to the U.S. Food and Drug Administrat...
Initial Study to Evaluate P harmacokinetics, Biomarkers and Safety of STAT-205 Targeting Preliminary Data 2022 FORT COLLINS, Colo., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB), a leading biopharmaceutical company creating next-genera...
Gainers: Siyata Mobile (NASDAQ:SYTA) +126%. Ensysce Biosciences (NASDAQ:ENSC) +94%. Trupanion (NASDAQ:TRUP) +35%. TESSCO Technologies (NASDAQ:TESS) +31%. Jumia (NYSE:JMIA) +25%. Novavax (NASDAQ:NVAX) +24%. Elevation Oncology (NASDAQ:ELEV) +22%. Statera Biopharma (NASDAQ:ST...
Statera Biopharma (NASDAQ:STAB) perks up 7.8% premarket following an announcement that the FDA has lifted the clinical hold placed on its Entolimod research and development activity in acute radiation syndrome (ARS). Based on the Company’s response, the FDA acknowle...
FORT COLLINS, Colo., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc . (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the U.S. Food and Drug Administration (FDA...
Statera Biopharma Inc. (STAB) Q3 2021 Earnings Conference Call November 15, 2021 5:30 PM ET Company Participants Nichol Ochsner – Executive Vice President-Investor Relations Michael K. Handley – President and Chief Executive Officer Peter Aronstam – Chief Financial Office...
Statera BioPharma (NASDAQ:STAB): Q3 GAAP EPS of -$0.47. Revenue of $236.5M Press Release For further details see: Statera BioPharma reports Q3 results
FORT COLLINS, Co., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today reported important corporate events and financial results fo...
FORT COLLINS, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will host a conference call and...
News, Short Squeeze, Breakout and More Instantly...
Statera Biopharma Inc. Company Name:
STAB Stock Symbol:
NASDAQ Market:
Statera Biopharma Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...